Finzati - Logo
BLRX logo

BioLineRx Ltd.

BLRX • Biotechnology
$2.67
▼ -0.02 (-0.74%)
Current price
EarningsSep 2, 11:12 AM UTC
New financial eventQ2 2026Mixed

BioLineRx Ltd. has reported Q2 2026 financial results

The latest report contains a combination of positive and negative financial changes. The stronger areas should be weighed against the weaker ones before drawing conclusions. The report may attract increased investor attention and price volatility.

Finzati signal
Mixed development
Sep 2, 11:12 AM UTC
Changed
-1.63%
Revenue
Improved
+21.88%
Net income
Changed
-1861.04%
Free cash flow
Changed
-53.56%
Cash
Improved
-37.67%
Total debt
What changed
↑Net income increased 21.9%, showing improved profitability.
↓Free cash flow declined 1861.0%, indicating pressure on cash generation.
↓Total debt declined 37.7%, modestly improving financial flexibility.
↓Cash and short-term investments declined 53.6%.
Based on newly processed financial statements and comparable prior-period data.This is informational analysis, not investment advice.
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Sep 2, 2026, 11:12 AM UTCLast profile update: Sep 2, 2026, 12:15 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$2.67
Change-0.74%
Shares Out4.43M
Market Cap$12.24M
Enterprise Value$2.72M
52W Range2.15 - 4.56
Beta0.71
P/E-1.38
P/S8.72
P/B0.73
P/FCF-1.56
EV/Sales1.94

Investment DNA

How strong this company looks for long-term investors

49
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
73/100
Growth Potential
Revenue and expansion
95/100
Price Attractiveness
Cheap or expensive today
59/100
Why this score▼
Positive revenue growth · 96.8%Manageable debt level · 0.56Healthy liquidity · 1.95Weak profitability

Analyst view

Analyst sentiment and price target

BLRX
Analyst sentiment
Based on 7 analyst votes · 2026-09-02
100/100
Bullish
Bullish
7
Hold
0
Bearish
0

Company Overview

IPO: 7/27/2011
Industry: Biotechnology
P/B i: 0.73
Debt / Equity i: 0.56
Operating Margin: -871.78%
Net Margin: -99.58%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.56
Current Ratio: 1.95
Quick Ratio: 1.78
Status: Good

Insider Transactions

Recent executive and insider activity

Yan Shaoyu
Transaction: 03/18/2026
OTHER
Change
0
Price
Not reported
Filing
04/10/2026
Type
OTHER
Molcho Avraham
Transaction: 01/01/2025
OTHER
Change
+2,055,000
Price
$0.05
Filing
03/31/2026
Type
OTHER
Dar Rami
Transaction: 01/01/2025
OTHER
Change
+2,055,000
Price
$0.05
Filing
03/31/2026
Type
OTHER